[en] This review emphasizes the safety profile of intra-articular hyaluronic acid treatment of knee
osteoarthritis, as well as its moderate but real efficacy on symptoms, which is in the same
range than other pharmacological modalities used in this indication. Effectiveness of intraarticular
hyaluronic acid has also been highlighted based on ‘real-life’ data, together with the
clinical benefit of systematic repeated treatment cycles, and the influence of the molecular
weight of hyaluronic acid on treatment outcome. These aspects should be particularly helpful
to clinicians when making personalized care decisions.
Disciplines :
Public health, health care sciences & services Rheumatology
Author, co-author :
Cooper, Cyrus
Rannou, François
Richette, Pascal
Bruyère, Olivier ; Université de Liège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Al-Daghri, Nasser
Altman, Roy D
Brandi, Maria Luisa
Collaud Basser, Sabine
Herrero-Beaumont, Gabriel
Migliore, Alberto
Pavelka, Karel
Uebelhart, Daniel
Reginster, Jean-Yves ; Université de Liège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage 2007;15:981–1000.
Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P, et al. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003;62:1145–55.
McAlindon TE, Bannuru RR, Sullivan MC, Arden NK, Berenbaum F, Bierma-Zeinstra SM, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage 2014;22:363–88.
Hochberg MC, Altman RD, April TK, Benkhalti M, Guyatt G, McGowan J, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) 2012;64:465–74.
National Institute for Health and Care Excellence. Clinical guideline CG177: osteoarthritis: care and management in adults. 2014. URL: http://www.nice.org.uk/guidance/cg177.
Bhala N, Emberson J, Merhi A, Abramson S, Arber N, et al, and the Coxib and Traditional NSAID Trialists' (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013;382:769–79.
Roberts E, Delgado Nunes V, Buckner S, Latchem S, Constanti M, Miller P, et al. Paracetamol: not as safe as we thought? A systematic literature review of observational studies. Ann Rheum Dis 2016;75:552–9.
Johnson VL, Hunter DJ. The epidemiology of osteoarthritis. Best Pract Res Clin Rheumatol 2014;28:5–15.
Axelrod L. Glucocorticoids. In: Kelley WN, Harris ED Jr, Ruddy S, Sledge CB, editors. Textbook of rheumatology. 4th ed. Philadelphia: WB Saunders; 1993. p. 779–96.
Lazarevic MB, Skosey JL, Djordjevic-Denic G, Swedler WI, Zgradic I, Myones BL. Reduction of cortisol levels after single intra-articular and intramuscular steroid injection. Am J Med 1995;99:370–3.
Wicki J, Droz M, Cirafici L, Vallotton MB. Acute adrenal crisis in a patient treated with intraarticular steroid therapy. J Rheumatol 2000;27:510–1.
Younes M, Neffati F, Touzi M, Hassen-Zrour S, Fendri Y, Bejia I, et al. Systemic effects of epidural and intra-articular glucocorticoid injections in diabetic and non-diabetic patients. Joint Bone Spine 2007;74:472–6.
Choudhry MN, Malik RA, Charalambous CP. Blood glucose levels following intra-articular steroid injections in patients with diabetes: a systematic review. JBJS Rev 2016;4.
Bruyère O, Cooper C, Pelletier JP, Branco J, Brandi ML, Guillemin F, et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum 2014;44:253–63.
Treatment of osteoarthritis of the knee: evidence-based guideline. 2nd ed. Rosemont (IL): American Academy of Orthopaedic Surgeons; 2013. URL: www.aaos.org/research/guidelines/TreatmentofOsteoarthritisoftheKneeGuideline.pdf.
Lo GH, LaValley M, McAlindon T, Felson DT. Intra-articular hyaluronic acid in treatment of knee osteoarthritis: a meta-analysis. JAMA 2003;290:3115–21.
Wang CT, Lin J, Chang CJ, Lin YT, Hou SM. Therapeutic effects of hyaluronic acid on osteoarthritis of the knee: a meta-analysis of randomized controlled trials. J Bone Joint Surg Am 2004;86A:538–45.
Arrich J, Piribauer F, Mad P, Schmid D, Klaushofer K, Müllner M. Intra-articular hyaluronic acid for the treatment of osteoarthritis of the knee: systematic review and meta-analysis. CMAJ 2005;172:1039–43.
Modawal A, Ferrer M, Choi HK, Castle JA. Hyaluronic acid injections relieve knee pain. J Fam Pract 2005;54:758–67.
Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev 2006:CD005321.
Medina JM, Thomas A, Denegar CR. Knee osteoarthritis: should your patient opt for hyaluronic acid injection? J Fam Pract 2006;55:669–75.
Reichenbach S, Blank S, Rutjes AW, Shang A, King EA, Dieppe PA, et al. Hylan versus hyaluronic acid for osteoarthritis of the knee: a systematic review and meta-analysis. Arthritis Rheum 2007;57:1410–8.
Bannuru RR, Natov NS, Obadan IE, Price LL, Schmid CH, McAlindon TE. Therapeutic trajectory of hyaluronic acid versus corticosteroids in the treatment of knee osteoarthritis: a systematic review and meta-analysis. Arthritis Rheum 2009;61:1704–11.
Colen S, van den Bekerom MP, Mulier M, Haverkamp D. Hyaluronic acid in the treatment of knee osteoarthritis: a systematic review and meta-analysis with emphasis on the efficacy of different products. Biodrugs 2012;26:257–68.
Rutjes AW, Jüni P, da Costa BR, Trelle S, Nüesch E, Reichenbach S. Viscosupplementation for osteoarthritis of the knee: a systematic review and meta-analysis. Ann Intern Med 2012;157:180–91.
Miller LE, Block JE. US-approved intra-articular hyaluronic acid injections are safe and effective in patients with knee osteoarthritis: systematic review and meta-analysis of randomized, saline-controlled trials. Clin Med Insights Arthritis Musculoskelet Disord 2013;6:57–63.
Bannuru RR, Vaysbrot EE, Sullivan MC, McAlindon TE. Relative efficacy of hyaluronic acid in comparison with NSAIDs for knee osteoarthritis: a systematic review and meta-analysis. Semin Arthritis Rheum 2014;43:593–9.
Bannuru RR, Schmid CH, Kent DM, Vaysbrot EE, Wong JB, McAlindon TE. Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis. Ann Intern Med 2015;162:46–54.
Richette P, Chevalier X, Ea HK, Eymard F, Henrotin Y, Ornetti P, et al. Hyaluronan for knee osteoarthritis: an updated meta-analysis of trials with low risk of bias. RMD Open 2015;1:e000071.
Petrella RJ, Wakeford C. Pain relief and improved physical function in knee osteoarthritis patients receiving ongoing hylan G-F 20, a high-molecular-weight hyaluronan, versus other treatment options: data from a large real-world longitudinal cohort in Canada. Drug Des Devel Ther 2015;9:5633–40.
Petrella RJ. Hyaluronic acid for the treatment of knee osteoarthritis: long-term outcomes from a naturalistic primary care experience. Am J Phys Med Rehabil 2005;84:278–83.
Waddell DD, Bricker DC. Clinical experience with the effectiveness and tolerability of hylan G-F 20 in 1047 patients with osteoarthritis of the knee. J Knee Surg 2006;19:19–27.
Kausch T, Lahne U, Thomas R, Kipshoven C, Schuld M. The intra-articular treatment of osteoarthritis with hyaluronic acid. Orthopädische Praxis 2009;45:258–66. In German.
Altman R, Lim S, Steen RG, Dasa V. Hyaluronic acid injections are associated with delay of total knee replacement surgery in patients with knee osteoarthritis: evidence from a large US health claims database. PLoS One 2015;10:e0145776.
Ong KL, Anderson AF, Niazi F, Fierlinger AL, Kurtz SM, Altman RD. Hyaluronic acid injections in Medicare knee osteoarthritis patients are associated with longer time to knee arthroplasty. J Arthroplasty 2016;31:1667–73.
Altman R, Fredericson M, Bhattacharyya SK, Bisson B, Abbott T, Yadalam S, et al. Association between hyaluronic acid injections and time-to-total knee replacement surgery. J Knee Surg 2015;29:564–70.
McAlindon TE, Bannuru RR. Osteoarthritis: is viscosupplementation really so unsafe for knee OA? Nat Rev Rheumatol 2012;8:635–6.
Cutolo M, Berenbaum F, Hochberg M, Punzi L, Reginster JY. Commentary on recent therapeutic guidelines for osteoarthritis. Semin Arthritis Rheum 2015;44:611–7.
Pagnano M, Westrich G. Successful nonoperative management of chronic osteoarthritis pain of the knee: safety and efficacy of retreatment with intra-articular hyaluronans. Osteoarthritis Cartilage 2005;13:751–61.
Leopold SS, Warme WJ, Pettis PD, Shott S. Increased frequency of acute local reaction to intra-articular hylan GF- 20 (Synvisc) in patients receiving more than one course of treatment. J Bone Joint Surg Am 2002;84A:1619–23.
Chen AL, Desai P, Adler EM, Di Cesare PE. Granulomatous inflammation after hylan G-F 20 viscosupplementation of the knee: a report of six cases. J Bone Joint Surg Am 2002;84A:1142–7.
Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G. Intraarticular corticosteroid for treatment of osteoarthritis of the knee. Cochrane Database Syst Rev 2006:CD005328.
Navarro-Sarabia F, Coronel P, Collantes E, Navarro FJ, de la Serna AR, Naranjo A, et al. A 40-month multicentre, randomised placebo-controlled study to assess the efficacy and carry-over effect of repeated intra-articular injections of hyaluronic acid in knee osteoarthritis: the AMELIA project. Ann Rheum Dis 2011;70:1957–62.
Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008;16:137–62.
American College of Rheumatology, Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 2000;43:1905–15.
Rosen J, Avram V, Fierlinger A, Niazi F, Sancheti P, Bedi A. Clinicians' perspectives on the use of intra-articular hyaluronic acid as a treatment for knee osteoarthritis: a North American, multidisciplinary survey. Clin Med Insights Arthritis Musculoskelet Disord 2016;9:21–7.
Migliore A, Bizzi E, Herrero-Beaumont J, Petrella RJ, Raman R, Chevalier X. The discrepancy between recommendations and clinical practice for viscosupplementation in osteoarthritis: mind the gap! Eur Rev Med Pharmacol Sci 2015;19:1124–9.
Bruyère O, Cooper C, Pelletier JP, Maheu E, Rannou F, Branco J, et al. A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis: from evidence-based medicine to the real-life setting. Semin Arthritis Rheum 2016;45:S3–11.
Altman RD, Schemitsch E, Bedi A. Assessment of clinical practice guideline methodology for the treatment of knee osteoarthritis with intra-articular hyaluronic acid. Semin Arthritis Rheum 2015;45:132–9.
Balazs EA. Viscoelastic properties of hyaluronic acid and biological lubrication. Univ of Mich Med Cent J 1968;33:255–9.
Balazs EA, Denlinger JL. Viscosupplementation: a new concept in the treatment of osteoarthritis. J Rheumatol 1993;20:3–9.
Altman RD, Manjoo A, Fierlinger A, Niazi F, Nicholls M. The mechanism of action for hyaluronic acid treatment in the osteoarthritic knee: a systematic review. BMC Musculoskelet Disord 2015;16:321.
Caires R, Luis E, Taberner FJ, Fernandez-Ballester G, Ferrer-Montiel A, Balazs EA, et al. Hyaluronan modulates TRPV1 channel opening, reducing peripheral nociceptor activity and pain. Nat Commun 2015;6:8095.
Gomez R, Villalvilla A, Largo R, Gualillo O, Herrero-Beaumont G. TLR4 signalling in osteoarthritis; finding targets for candidate DMOADs. Nat Rev Rheumatol 2015;11:159–70.
Campo GM, Avenoso A, Campo S, D'Ascola A, Traina P, Calatroni A. Differential effect of molecular size HA in mouse chondrocytes stimulated with PMA. Biochim Biophys Acta 2009;1790:1353–67.
Pham T, van der Heijde D, Altman RD, Anderson JJ, Bellamy N, Hochberg M, et al. OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthritis Cartilage 2004;12:389–99.
Berenbaum F, Grifka J, Cazzaniga S, D'Amato M, Giacovelli G, Chevalier X, et al. A randomised, double-blind, controlled trial comparing two intra-articular hyaluronic acid preparations differing by their molecular weight in symptomatic knee osteoarthritis. Ann Rheum Dis 2012;71:1454–60.
Karlsson J, Sjögren LS, Lohmander LS. Comparison of two hyaluronan drugs and placebo in patients with knee osteoarthritis: a controlled, randomized, double-blind, parallel-design multicentre study. Rheumatology (Oxford) 2002;41:1240–8.
Kirchner M, Marshall D. A double-blind randomized controlled trial comparing alternate forms of high molecular weight hyaluronan for the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage 2006;14:154–62.
Jüni P, Reichenbach S, Trelle S, Tschannen B, Wandel S, Jordi B, et al. Efficacy and safety of intraarticular hylan or hyaluronic acids for osteoarthritis of the knee: a randomized controlled trial. Arthritis Rheum 2007;56:3610–9.
Maheu E, Zaim M, Appelboom T, Jeka S, Trc T, Berenbaum F, et al. Comparative efficacy and safety of two different molecular weight (MW) hyaluronans F60027 and hylan G-F 20 in symptomatic osteoarthritis of the knee (KOA): results of a non inferiority, prospective, randomized, controlled trial. Clin Exp Rheumatol 2011;29:527–35.
Pavelka K, Uebelhart D. Efficacy evaluation of highly purified intra-articular hyaluronic acid (Sinovial) vs hylan G-F 20 (Synvisc) in the treatment of symptomatic knee osteoarthritis: a double-blind, controlled, randomized, parallel-group non-inferiority study. Osteoarthritis Cartilage 2011;19:1294–300.
Dreiser RL, Avouac B, Bardin T. A 6 month trial evaluating efficacy of one intraarticular injection of 2 per cent sodium hyaluronate versus hylan G F 20 in the treatment of painful tibiofemoral osteoarthritis [abstract]. Ann Rheum Dis 2015;Suppl 2:376.
Waddell D, Rein A, Panarites C, Coleman PM, Weiss C. Cost implications of introducing an alternative treatment for patients with osteoarthritis of the knee in a managed care setting. Am J Manag Care 2001;7:981–91.
Torrance GW, Raynauld JP, Walker V, Goldsmith CH, Bellamy N, Band PA, et al. A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 2 of 2): economic results. Osteoarthritis Cartilage 2002;10:518–27.
Kahan A, Lleu PL, Salin L. Prospective randomized study comparing the medicoeconomic benefits of hylan GF-20 vs. conventional treatment in knee osteoarthritis. Joint Bone Spine 2003;70:276–81.
Yen ZS, Lai MS, Wang CT, Chen LS, Chen SC, Chen WJ, et al. Cost-effectiveness of treatment strategies for osteoarthritis of the knee in Taiwan. J Rheumatol 2004;31:1797–803.
Mazières B, Bard H, Ligier M, Bru I, d'Orsay GG, le Pen C. Medicoeconomic evaluation of hyaluronic acid for knee osteoarthritis in everyday practice: the MESSAGE study. Joint Bone Spine 2007;74:453–60.
Turajane T. Cost analysis of intra-articular sodium hyaluronate treatment in knee osteoarthritis patients who failed conservative treatment. J Med Assoc Thai 2007;90:1839–44.
Chou CW, Lue KH, Lee HS, Lin RC, Lu KH. Hylan G-F 20 has better pain relief and cost-effectiveness than sodium hyaluronate in treating early osteoarthritic knees in Taiwan. J Formos Med Assoc 2009;108:663–72.
Miller LE, Block JE. An 8-week knee osteoarthritis treatment program of hyaluronic acid injection, deliberate physical rehabilitation, and patient education is cost effective at 2 years follow-up: the OsteoArthritis Centers of America Experience. Clin Med Insights Arthritis Musculoskelet Disord 2014;7:49–55.
Hatoum HT, Fierlinger AL, Lin SJ, Altman RD. Cost-effectiveness analysis of intra-articular injections of a high molecular weight bioengineered hyaluronic acid for the treatment of osteoarthritis knee pain. J Med Econ 2014;17:326–37.
Raynauld JP, Torrance GW, Band PA, Goldsmith CH, Tugwell P, Walker V, et al. A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (part 1 of 2): clinical results. Osteoarthritis Cartilage 2002;10:506–17.
Turajane T. Outcomes of intra-articular injection of sodium hyaluronate for the treatment of osteoarthritis of the knee. J Med Assoc Thai 2007;90:1845–52.
Miller LE, Block JE. An 8-week multimodal treatment program improves symptoms of knee osteoarthritis: a real-world multicenter experience. Pragmatic Observational Res 2013;4:39–44.
Altman RD, Rosen JE, Bloch DA, Hatoum HT, Korner P. A double-blind, randomized, saline-controlled study of the efficacy and safety of Euflexxa for treatment of painful osteoarthritis of the knee, with an open-label safety extension (the FLEXX trial). Semin Arthritis Rheum 2009;39:1–9.
Altman RD, Rosen JE, Bloch DA, Hatoum HT. Safety and efficacy of retreatment with a bioengineered hyaluronate for painful osteoarthritis of the knee: results of the open-label extension Study of the FLEXX Trial. Osteoarthritis Cartilage 2011;19:1169–75.